Madhukar Pai*, Andrew Ramsay, Richard O’Brien

There is great excitement in the tuberculosis (TB) scientific community over the introduction of new tools into TB control activities. The development of new tools is an important component of the Global Plan to Stop TB and the World Health Organization’s new global Stop TB Strategy [1,2]. Anticipating the introduction of new tools, the Stop TB Partnership has established a Retooling Task Force to develop a framework for engaging policy makers to foster accelerated adoption and implementation of new tools into TB control programs [3].


Yasir A.W. Skeiky, Mark R. Alderson, Pamela J. Ovendale, Yves Lobet, Wilfried Dalemans, Ian M. Ormec, Steven G. Reedd, Antonio Campos-Neto

Received 9 September 2004; received in revised form 28 January 2005; accepted 3 March 2005
Available online 30 March 2005

Health care for every American may be the current test of the strength of our convictions, as civil rights was in the 1960s.

by Jeanne M. Lambrew, John D. Podesta, and Teresa L. Shaw

ABSTRACT: Some speculate that Americans are neither politically capable of nor morally committed to solving the health system problems. We disagree. We propose a plan that insures all and improves the value and cost-effectiveness of health care by knitting together employer-sponsored insurance and Medicaid; promoting prevention, research, and information technology; and financing its investments through a dedicated value-added tax. By prioritizing practicality, fairness, and responsibility, the plan aims to avoid ideological battles and prevent fear of major change. By emphasizing the moral imperative for change, especially relative to other options on the policy agenda, it aims to create momentum for expanding and improving health coverage for all.

Jan A.M. Langermansa, T. Mark Dohertyb, Richard A.W. Vervennea, Tridia van der Laanc, Konstantin Lyashchenkod, Rena Greenwaldd, Else Marie Aggerb, Claus Aagaardb, HorstWeilere, Dick van Soolingenc, Wilfried Dalemansf, Alan W. Thomasa, Peter Andersen

Received 24 June 2004; received in revised form 15 October 2004; accepted 9 November 2004
Available online 15 December 2004

K. F. Laserson, N. J. Binkin, L. E. Thorpe, R. Laing, M. F. Iademarco, A. Bloom, T. B. Agerton, L. Nelson, J. P. Cegielski, O. Ferroussier, T. Holtz, E. Vitek, V. Gammino, K. Tan, A. Finlay, P. Dewan, A. Miranda, G. Aquino, K. Weyer, D. N. Sy, A. Vernon, J. Becerra, J. Ershova,§§ C. D. Wells


SETTING: In resource-poor countries, few tuberculosis (TB) program staff at the national, provincial, and even district levels have the basic analytical and epidemiological skills necessary for collecting and analyzing quality data pertaining to national TB control program (NTP) improvements. This includes setting program priorities, operations planning, and implementing and evaluating program activities.

The Magic Bullets And Tuberculosis Drug Targets

Abstract: Modern chemotherapy has played a major role in our control of tuberculosis. Yet tuberculosis still remains a leading infectious disease worldwide, largely owing to persistence of tubercle bacillus and inadequacy of the current chemotherapy. The increasing emergence of drug-resistant tuberculosis along with the HIV pandemic threatens disease control and highlights both the need to understand how our current drugs work and the need to develop new and more effective drugs. This review provides a brief historical account of tuberculosis drugs, examines the problem of current chemotherapy, discusses the targets of current tuberculosis drugs, focuses on some promising new drug candidates, and proposes a range of novel drug targets for intervention. Finally, this review addresses the problem of conventional drug screens based on inhibition of replicating bacilli and the challenge to develop drugs that target nonreplicating persistent bacilli. A new generation of drugs that target persistent bacilli is needed for more effective treatment of tuberculosis.

Sobre a REDE-TB

A Rede Brasileira de Pesquisa em Tuberculose (REDE-TB) é uma Organização Não Governamental (ONG) de direito privado sem fins lucrativos, preocupada em auxiliar no desenvolvimento não só de novos medicamentos, novas vacinas, novos testes diagnósticos e novas estratégias de controle de TB, mas também na validação dessas inovações tecnológicas, antes de sua comercialização no país e/ou de sua implementação nos Programa de Controle de TB no País.




Tel: +55 (21)3938 - 2426
Tel/ Fax: +55 (21)3938 - 2431.

Endereço: Avenida Carlos Chagas Filho, 791, Cidade Universitária - Ilha do Fundão, Rio de Janeiro, RJ - Brasil. CEP: 21941-904

Assine a newsletter da REDE-TB

Curta REDE-TB no Facebook